Precision BioSciences prices offering of shares, pre-funded warrants at $7.75 each

• Precision BioSciences entered a November 5, 2026, underwriting agreement to sell 10,235,077 common shares at $7.75 each.
• The offering also includes pre-funded warrants to purchase up to 5,893,964 common shares at $7.749995 per warrant in lieu of common stock.
• Net proceeds, existing cash, operating discipline and at-the-market facility availability are expected to provide cash runway into the fourth quarter of 2029.
• That runway is expected to fund the PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-071867), on November 09, 2026, and is solely responsible for the information contained therein.